GLPG vs. BBIO, LEGN, ELAN, CYTK, GRFS, NUVL, VKTX, AXSM, TGTX, and KRYS
Should you be buying Galapagos stock or one of its competitors? The main competitors of Galapagos include BridgeBio Pharma (BBIO), Legend Biotech (LEGN), Elanco Animal Health (ELAN), Cytokinetics (CYTK), Grifols (GRFS), Nuvalent (NUVL), Viking Therapeutics (VKTX), Axsome Therapeutics (AXSM), TG Therapeutics (TGTX), and Krystal Biotech (KRYS). These companies are all part of the "pharmaceutical products" industry.
Galapagos vs.
BridgeBio Pharma (NASDAQ:BBIO) and Galapagos (NASDAQ:GLPG) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, community ranking, dividends, risk, media sentiment, institutional ownership, earnings, profitability and analyst recommendations.
In the previous week, BridgeBio Pharma had 17 more articles in the media than Galapagos. MarketBeat recorded 21 mentions for BridgeBio Pharma and 4 mentions for Galapagos. Galapagos' average media sentiment score of 0.47 beat BridgeBio Pharma's score of 0.43 indicating that Galapagos is being referred to more favorably in the news media.
BridgeBio Pharma presently has a consensus target price of $48.08, suggesting a potential upside of 42.28%. Galapagos has a consensus target price of $30.75, suggesting a potential upside of 29.42%. Given BridgeBio Pharma's stronger consensus rating and higher probable upside, equities analysts plainly believe BridgeBio Pharma is more favorable than Galapagos.
99.8% of BridgeBio Pharma shares are held by institutional investors. Comparatively, 32.5% of Galapagos shares are held by institutional investors. 24.7% of BridgeBio Pharma shares are held by company insiders. Comparatively, 2.9% of Galapagos shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Galapagos has higher revenue and earnings than BridgeBio Pharma.
Galapagos received 298 more outperform votes than BridgeBio Pharma when rated by MarketBeat users. However, 71.19% of users gave BridgeBio Pharma an outperform vote while only 64.01% of users gave Galapagos an outperform vote.
Galapagos has a net margin of 0.00% compared to BridgeBio Pharma's net margin of -201.53%.
BridgeBio Pharma has a beta of 1.05, meaning that its stock price is 5% more volatile than the S&P 500. Comparatively, Galapagos has a beta of 0.21, meaning that its stock price is 79% less volatile than the S&P 500.
Summary
BridgeBio Pharma beats Galapagos on 9 of the 15 factors compared between the two stocks.
Get Galapagos News Delivered to You Automatically
Sign up to receive the latest news and ratings for GLPG and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Galapagos Competitors List
Related Companies and Tools
This page (NASDAQ:GLPG) was last updated on 1/18/2025 by MarketBeat.com Staff
Free GLPG Stock Alerts